Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas.
Friedrich M, Sankowski R, Bunse L, Kilian M, Green E, Ramallo Guevara C, Pusch S, Poschet G, Sanghvi K, Hahn M, Bunse T, Münch P, Gegner HM, Sonner JK, von Landenberg A, Cichon F, Aslan K, Trobisch T, Schirmer L, Abu-Sammour D, Kessler T, Ratliff M, Schrimpf D, Sahm F, Hopf C, Heiland DH, Schnell O, Beck J, Böttcher C, Fernandez-Zapata C, Priller J, Heiland S, Gutcher I, Quintana FJ, von Deimling A, Wick W, Prinz M, Platten M. Friedrich M, et al. Among authors: bunse l, bunse t. Nat Cancer. 2021 Jul;2(7):723-740. doi: 10.1038/s43018-021-00201-z. Epub 2021 May 24. Nat Cancer. 2021. PMID: 35121943
Concepts in glioma immunotherapy.
Platten M, Bunse L, Wick W, Bunse T. Platten M, et al. Among authors: bunse l, bunse t. Cancer Immunol Immunother. 2016 Oct;65(10):1269-75. doi: 10.1007/s00262-016-1874-x. Epub 2016 Jul 26. Cancer Immunol Immunother. 2016. PMID: 27460064 Free PMC article. Review.
K27M-mutant histone-3 as a novel target for glioma immunotherapy.
Ochs K, Ott M, Bunse T, Sahm F, Bunse L, Deumelandt K, Sonner JK, Keil M, von Deimling A, Wick W, Platten M. Ochs K, et al. Among authors: bunse l, bunse t. Oncoimmunology. 2017 May 12;6(7):e1328340. doi: 10.1080/2162402X.2017.1328340. eCollection 2017. Oncoimmunology. 2017. PMID: 28811969 Free PMC article.
Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.
Blaes J, Thomé CM, Pfenning PN, Rübmann P, Sahm F, Wick A, Bunse T, Schmenger T, Sykora J, von Deimling A, Wiestler B, Merz C, Jugold M, Haberkorn U, Abdollahi A, Debus J, Gieffers C, Kunz C, Bendszus M, Kluge M, Platten M, Fricke H, Wick W, Lemke D. Blaes J, et al. Among authors: bunse t. Mol Cancer Res. 2018 May;16(5):767-776. doi: 10.1158/1541-7786.MCR-17-0563. Epub 2018 Feb 16. Mol Cancer Res. 2018. PMID: 29453321
Vaccine Strategies in Gliomas.
Platten M, Bunse L, Riehl D, Bunse T, Ochs K, Wick W. Platten M, et al. Among authors: bunse l, bunse t. Curr Treat Options Neurol. 2018 Mar 28;20(5):11. doi: 10.1007/s11940-018-0498-1. Curr Treat Options Neurol. 2018. PMID: 29594595 Review.
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.
Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Eisel J, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger MC, Harter PN, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende C, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suvà ML, Niemeyer BA, von Deimling A, Wick W, Platten M. Bunse L, et al. Among authors: bunse t. Nat Med. 2018 Aug;24(8):1192-1203. doi: 10.1038/s41591-018-0095-6. Epub 2018 Jul 9. Nat Med. 2018. PMID: 29988124
A vaccine targeting mutant IDH1 in newly diagnosed glioma.
Platten M, Bunse L, Wick A, Bunse T, Le Cornet L, Harting I, Sahm F, Sanghvi K, Tan CL, Poschke I, Green E, Justesen S, Behrens GA, Breckwoldt MO, Freitag A, Rother LM, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Stevanovic S, Tabatabai G, Steinbach JP, Bendszus M, von Deimling A, Schmitt M, Wick W. Platten M, et al. Among authors: bunse l, bunse t. Nature. 2021 Apr;592(7854):463-468. doi: 10.1038/s41586-021-03363-z. Epub 2021 Mar 24. Nature. 2021. PMID: 33762734 Free PMC article. Clinical Trial.
Genetically Modified Cellular Therapies for Malignant Gliomas.
Kilian M, Bunse T, Wick W, Platten M, Bunse L. Kilian M, et al. Among authors: bunse l, bunse t. Int J Mol Sci. 2021 Nov 26;22(23):12810. doi: 10.3390/ijms222312810. Int J Mol Sci. 2021. PMID: 34884607 Free PMC article. Review.
AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas.
Bunse L, Rupp AK, Poschke I, Bunse T, Lindner K, Wick A, Blobner J, Misch M, Tabatabai G, Glas M, Schnell O, Gempt J, Denk M, Reifenberger G, Bendszus M, Wuchter P, Steinbach JP, Wick W, Platten M. Bunse L, et al. Among authors: bunse t. Neurol Res Pract. 2022 May 23;4(1):20. doi: 10.1186/s42466-022-00184-x. Neurol Res Pract. 2022. PMID: 35599302 Free PMC article.
55 results